Brain and behavior · 2026
Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simón-Vicente Lucía, Calvo Sara, Mariscal Natividad, Muñoz-Siscart Ignacio, Diaz-Piñeiro Dolores, Rivadeneyra Jéssica, Cubo Esther
Аннотация
INTRODUCTION: Huntington's disease (HD) is a neurodegenerative disorder characterised by motor dysfunction, cognitive impairment, and psychiatric disturbances. This study analyzed the relationship between clinical characteristics, sarcopenia, and physical activity (PA) levels in HD patients.
METHODS: A 1-year observational study was conducted with symptomatic, ambulatory HD patients, assessed at baseline and after 12 months. PA was monitored using a Fitbit Charge 4 activity tracker, and sarcopenia was determined through assessments of muscle strength, quantity, and physical performance. Participants were classified into two clusters based on age, motor (Unified HD Rating Scale), and cognitive function (Mini-Mental State Examination).
RESULTS: We included 33 subjects with HD, mean age 53 (40-60) years, 45.5% males, median TFC 9.5 (7-13). At baseline, Cluster 1 had better motor function, functional capacity, and less apathy with a positive trend for higher PA, compared with Cluster 2, which had a negative trend for decreased PA over time (p = 0.006). After 1 year, Cluster 1 showed a decrease in PA (p = 0.035), similar to Cluster 2. At baseline, 53% of participants in Cluster 2 presented probable or confirmed sarcopenia, compared with 13% in Cluster 1. Significant differences (p < 0.05) were observed in muscle strength, bioelectrical impedance analysis (BIA), and SPPB scores, with higher values in Cluster 1.
CONCLUSIONS: These preliminary findings suggest that a reduction in PA using wearable technology may be a potential early indicator of functional changes in HD. Identifying when PA reduction begins can help determine the timing of interventions aimed at delaying disease progression.
METHODS: A 1-year observational study was conducted with symptomatic, ambulatory HD patients, assessed at baseline and after 12 months. PA was monitored using a Fitbit Charge 4 activity tracker, and sarcopenia was determined through assessments of muscle strength, quantity, and physical performance. Participants were classified into two clusters based on age, motor (Unified HD Rating Scale), and cognitive function (Mini-Mental State Examination).
RESULTS: We included 33 subjects with HD, mean age 53 (40-60) years, 45.5% males, median TFC 9.5 (7-13). At baseline, Cluster 1 had better motor function, functional capacity, and less apathy with a positive trend for higher PA, compared with Cluster 2, which had a negative trend for decreased PA over time (p = 0.006). After 1 year, Cluster 1 showed a decrease in PA (p = 0.035), similar to Cluster 2. At baseline, 53% of participants in Cluster 2 presented probable or confirmed sarcopenia, compared with 13% in Cluster 1. Significant differences (p < 0.05) were observed in muscle strength, bioelectrical impedance analysis (BIA), and SPPB scores, with higher values in Cluster 1.
CONCLUSIONS: These preliminary findings suggest that a reduction in PA using wearable technology may be a potential early indicator of functional changes in HD. Identifying when PA reduction begins can help determine the timing of interventions aimed at delaying disease progression.